{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:54:10Z","timestamp":1740174850793,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Everolimus is a mechanistic-target-of-rapamycin (mTOR) inhibitor bearing a potent antitumor effect against hormone receptor-positive breast cancer. Here, we report the case of a patient with recurrent breast cancer who developed osteomyelitis during the treatment with everolimus plus exemestane.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 56-year-old woman with early-stage breast cancer underwent right mastectomy and axillary lymph node dissection at the age of 45. Four years after the surgery, she experienced relapse at the chest wall. Radiotherapy was performed on the chest wall, including the sternum, and denosumab was administered. After several regimens of hormonal therapies, everolimus in combination with exemestane was administered. Three months later, the patient visited our clinic because of continuous fever. A computed tomography scan showed an osteolytic change in the sternal bone with pneumomediastinum, which indicated sternal osteomyelitis. Extensive debridement followed by secondary reconstruction of the chest wall was successfully performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Everolimus may cause osteomyelitis of the affected bone as a result of tumor necrosis. Everolimus-induced osteomyelitis may be manageable by extensive debridement performed without delay.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-022-01376-y","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T09:02:42Z","timestamp":1643360562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer"],"prefix":"10.1186","volume":"8","author":[{"given":"Kaori","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-9877","authenticated-orcid":false,"given":"Masafumi","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Sota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Tanei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Kagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"339","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974\u201384.","journal-title":"N Engl J Med"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139.","journal-title":"N Engl J Med"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369\u201379.","journal-title":"Lancet"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar J, Maity A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.","journal-title":"Front Mol Neurosci"},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31.","journal-title":"Cell Biosci"},{"issue":"403\u20134","key":"1376_CR7","first-page":"406","volume":"20","author":"PH Cottu","year":"2011","unstructured":"Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound Care. 2011;20(403\u20134):406.","journal-title":"J Wound Care."},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995\u20134004.","journal-title":"Mol Cell Biol"},{"key":"1376_CR9","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541\u20135.","journal-title":"Cancer Res"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46:57\u201364.","journal-title":"Semin Oncol"},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/mco.2020.2190","volume":"14","author":"H Iwasaki","year":"2021","unstructured":"Iwasaki H, Toda S, Murayama D, Kato S, Matsui A. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. Mol Clin Oncol. 2021;14:28.","journal-title":"Mol Clin Oncol"},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0167-8140(96)01880-4","volume":"42","author":"MK Tibbs","year":"1997","unstructured":"Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol. 1997;42:99\u2013106.","journal-title":"Radiother Oncol"},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.coms.2015.06.002","volume":"27","author":"MR Allen","year":"2015","unstructured":"Allen MR. Medication-related osteonecrosis of the jaw: basic and translational science updates. Oral Maxillofac Surg Clin North Am. 2015;27:497\u2013508.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1010-7940(01)00676-5","volume":"19","author":"M De Feo","year":"2001","unstructured":"De Feo M, Gregorio R, Della Corte A, Marra C, Amarelli C, Renzulli A, et al. Deep sternal wound infection: the role of early debridement surgery. Eur J Cardiothorac Surg. 2001;19:811\u20136.","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-022-01376-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T09:14:12Z","timestamp":1643361252000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-022-01376-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1186\/s40792-022-01376-y","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}